Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

PHASE3CompletedINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

August 21, 2019

Study Completion Date

September 4, 2019

Conditions
Candida Vulvovaginitis
Interventions
DRUG

Ibrexafungerp

Ibrexafungerp 300 mg BID for 1 day

DRUG

Placebo

Matching placebo

Trial Locations (25)

21740

Unified Women's Clinical Research- Hagerstown, Hagerstown

23502

Group For Women, Norfolk

27103

Unified Women's Clinical Research - Lyndhurst Clinical Research, Winston-Salem

27408

Unified Women's Clinical Research Greensboro, Greensboro

27607

Unified Women's Clinical Research Raleigh, Raleigh

27612

GYN Center for Women PA, Durham

27713

Carolina Women's Research and Wellness Center, Durham

28557

Unified Women's Clinical Research, Morehead City

29414

Medical Research South, Charleston

29572

Magnolia Ob/Gyn Research Center, LLC, Myrtle Beach

33186

New Age Medical Research Corporation, Miami

33461

Altus Research, Lake Worth

33759

Women's Medical Research Group, Clearwater

34748

OBGYN Assoc of Mid Florida, Leesburg

35294

University of Alabama at Birmingham, Birmingham

38120

Medical Research Center of Memphis, Memphis

48201

Wayne State University, Detroit

63131

Consultants In Women's Healthcare, Inc., St Louis

70006

Clinical Trials Management LLC, Covington

Clinical Trials Management LLC, Metairie

77054

TMC Life Research Inc, Houston

85032

Precision Trials AZ, LLC, Phoenix

92111

Womens' Health Care Research Corp, San Diego

08648

Center For Women's Health and Wellness LLC - Interspond - PPDS, Lawrenceville

Lawrence OB/GYN Clinical Research, LLC, Lawrenceville

All Listed Sponsors
lead

Scynexis, Inc.

INDUSTRY

NCT03734991 - Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) | Biotech Hunter | Biotech Hunter